ADVERTISEMENT

Indian Pharma Market Posts 6% Revenue Growth In October

Overall growth was driven by growth in price increase of 5.2% year on year and new launches which increased 2.7% year on year.

<div class="paragraphs"><p>Leading the pack, Glenmark Pharmaceuticals Ltd. achieved a growth rate of 13.8%, marking the highest in this group. (Photo source: Freepik)</p></div>
Leading the pack, Glenmark Pharmaceuticals Ltd. achieved a growth rate of 13.8%, marking the highest in this group. (Photo source: Freepik)

Indian Pharmaceuticals Market continued to report mid-single digit growth on year on year basis in October. IPM sales grew by 6.1% year on year during the month, against growth of 5.3% in September 2024 and 13.7% growth in October 2023.

Overall growth was driven by growth in price increase of 5.2% year on year and new launches which increased 2.7% year on year, while volume growth (negative 1.8% YoY) remained weak.

During January-October, IPM reported growth at an average of 7.5% year on year, where volume growth stood at average negative 1.0% year on year, according to AIOCD-AWACS data. Therapies such as cardiac, gastro, anti-diabetic, derma, and CNS have outperformed the IPM growth in October, while anti-infectives and respiratory delivered weak growth.

"Ind-Ra expect IPM growth to be at 8-9% year-on-year for FY25, against 6.5% YoY. In FY24 and 9.9% YoY growth in FY23,” said Krishnanath Munde, associate director at India Ratings and Research.

Key Highlights

  • Volume growth declined 1.8%. It had increased 5% in October 2023.

  • Price growth of 5.2% in October this year, as compared to 5.3% over the same period last year.

  • New launches increased 2.7%, as against 3.4% in October 2023.

MAT Performance

The moving annual total—or the 12-month rolling sales of overall pharma products—increased 7.6% in October.

Outperformers

Leading the pack, Glenmark Pharmaceuticals Ltd. achieved a growth rate of 13.8%, marking the highest in this group. Sun Pharmaceuticals Industries Ltd. also demonstrated strong performance at 13.1%, followed closely by Torrent Pharmaceuticals Ltd. at 11.7% and Indoco Remedies at 11.2%.

Cipla Ltd. (10.6%) and Ajanta Pharma Ltd. (9.2%) also exceeded IPM growth, showcasing their competitive strength in the market. Other notable outperformers include FDC (9.5%), Eris Lifesciences Ltd. (8.6%), Alkem Laboratories Ltd. (7.2%), Abbott India Ltd. (7.3%), and GlaxoSmithKline Pharma (6.5%), each achieving growth above the IPM average

Opinion
Glenmark Pharmaceuticals' US Arm Recalls Products Over Manufacturing Issues

Underperformers

On the other hand, several companies underperformed relative to the IPM growth. Mankind Pharma Ltd. and Lupin Ltd. each posted 4.1% growth, trailing the market benchmark. Zydus Lifesciences Ltd. and Dr. Reddy’s Laboratories Ltd. delivered modest growth at 5.2% and 5.9%, respectively.

Ipca Laboratories Ltd. came in at 5.1%, while JB Chemicals & Pharmaceuticals Ltd. achieved 4.4%. Emcure Pharmaceuticals Ltd. (2.9%), Alembic Pharmaceuticals Ltd. (2.2%), and Pfizer India (1.4%) also saw growth levels that lagged behind IPM. Notably, Sanofi India experienced a contraction, posting -2.1%, indicating challenges in maintaining market share.

Opinion
Aurobindo Pharma's Subsidiary Receives GMP From European Medicines Agency For Biosimilars Facility